Table 2.
Summary of relative risks (RRs) for association of age at menopause with risk of the endometrial cancer.
| Stratification | Number of studies | RR (95% CI) | I 2,% | P for heterogeneity |
|---|---|---|---|---|
| All studies | 18 | 1.89 (1.58-2.26) | 45.0% | 0.021 |
| Continent | ||||
| North America | 9 | 1.60 (1.37-1.86) | 0.0% | 0.516 |
| Asia | 5 | 3.06 (1.64-5.72) | 63.5% | 0.027 |
| Europe | 4 | 2.19 (1.74-2.75) | 0.0% | 0.453 |
| Study Design | ||||
| Case-control study | 9 | 1.80 (1.36-2.38) | 54.5% | 0.024 |
| Cohort study | 9 | 1.98 (1.56-2.52) | 35.4% | 0.135 |
| Menopausal type | ||||
| Natural menopause | 6 | 1.72 (1.09-2.71) | 67.1% | 0.009 |
| Natural menopause and surgical menopause | 5 | 2.25 (1.31-3.85) | 64.0% | 0.025 |
| NA | 7 | 1.94 (1.63-2.30) | 0.0% | 0.729 |
| Reference group of menopausal age | ||||
| ≤45 (<45 or ≤45 or ≤40) | 12 | 2.06 (1.51-2.81) | 60.6% | 0.003 |
| ≤50 (<50 or ≤50 or ≤47) | 6 | 1.79 (1.52-2.10) | 0.0% | 0.761 |
| The Newcastle-Ottawa score | ||||
| 6 or 7 | 5 | 1.59 (1.18-2.15) | 27.1% | 0.241 |
| 8 or 9 | 13 | 2.05 (1.64-2.56) | 50.8% | 0.018 |
RR, relative risk; CI, confidence interval; BMI, body mass index; PMH, postmenopausal hormone